ALNYLAM PHARMACEUTICALS, INC. Current State and Local Tax Expense (Benefit)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Current State and Local Tax Expense (Benefit) of $1.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2025 was $1.93M, a 20.88% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2024 was $1.60M, a 60.22% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2023 was $4.02M.
| Period end | Current State and Local Tax Expense (Benefit) 12 month | Current State and Local Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.93M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $1.60M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $4.02M 10-K · filed 2026-02-12 | $4.00M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |